Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Cardioprotective Effect of Dapagliflozin on Anthracyclines-Induced Cardiotoxicity in Breast Cancer Patients

NCT06491680 is registered in ClinicalTrials.gov with Helwan University as lead sponsor.

NCT NCT06491680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06491680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Cardioprotective Effect of Dapagliflozin on Anthracyclines-Induced Cardiotoxicity in Breast Cancer Patients
Lead sponsor
Helwan University
Phase
Phase 4
Overall status
Recruiting
Start date
September 10, 2024
Completion date
June 30, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer